Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
19 people get BIS articles and Market Currents by email alert.
Get email alerts on BIS »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
Best In Class Healthcare And Biotech ETFsBarchart's ETF Recommendations • Tue, Sep 20, 2011 -
Biotechs: Revenues Rise, But So Do Cutbacks in R&DPharmalot • Mon, Aug 1, 2011 -
-
-
-
-
-
Dissipate the Risk in Biotechnology With ETFsTom Lydon • Wed, Jan 19, 2011 -
-
-
-
ETF Stats for April 2010: SEA Forced to CloseRon Rowland • Mon, May 3, 2010 -
There are no Transcripts on BIS.
There are no News articles on BIS.
BIS vs. ETF Alternatives
BIS Description
ProShares UltraShort Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to twice (200%) the inverse (opposite) of the daily performance of the NASDAQ Biotechnology® Index.
See more details on sponsor's website
See more details on sponsor's website
Sector: Healthcare
Country: United States
Key Info
- In Your Portfolio: A Guide to Sector ETFs, A Guide to Healthcare, Pharma and Biotech ETFs
- Asset Class Performance: Sectors
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, March 12, 2012, 12:07 PM Shares of Anthera Pharmaceuticals (ANTH -52.1%) can't stop the freefall that was triggered by Friday's announcement that it's canceling its late-stage trial of its experimental treatment for heart disease. Adam Feuerstein eyes the recent carnage with a number of biotech names to conclude that "fail" is now re-entering the lexicon of investors in the sector. Comment! [On the Move, Healthcare, Quick Ideas]
- Thursday, August 4, 2011, 4:05 PM Dendreon (DNDN -67.4%) takes down an entire industry, with the Amex Biotech index falling an astonishing 10.4%. "Biotech risk takers burned on this one might be less risk tolerant going forward," one analyst explains. "The biotech group does work like that, especially for product failures." IBB -7.9%. XBI -9.8%. Comment! [Healthcare, On the Move, Top Stories]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Central Bank News
OFFSHORE RENMINBI LIKELY TO FOLLOW IN EURODOLLAR FOOTSTEPS-BIS http://bit.ly/Mo1U9x CYB CNY - View all 0 replies
-
Central Bank News
EMERGING MARKETS NOW ABLE TO COUNTER DOWNTURNS - BIS http://bit.ly/Mo1FeP FXI VWO EEM - View all 0 replies
-
Central Bank News
Optimism over global recovery evaporates, emerging economies bright spot - BIS http://bit.ly/K6lmTa - View all 0 replies
-
Justin M. Hall
4/5/12 7:30A ET: {BIS, SPPI} Short Biotech => Back on 1/30/12, I reco'd near-the-money puts on SPPI. Were you paying attention? - View all 16 replies
-
-
-
Justin M. Hall
4/5/12 3:45A ET: { Short Biotech } Reiterating my past take => Look for a bifurcated market to emerge in Q2 2012. I like BIS right now. - View all 2 replies
-
Justin M. Hall: Shares of BIS last traded at $22.86. I officially recommended it on my site at/below $24.
-
Justin M. Hall: I first highlighted the bifurcarted market theme on 3/8/12. Others are beginning to catch on. :-)
-
Justin M. Hall
3/21/12 2:05P ET: [ IBB ] When IBB hits $122, it's time to get short. Consider playing BIS. I continue to like this play at/below $24. - View all 5 replies
-
Justin M. Hall: It might require some work. We did very well with it last year. No BS. I like BIS right here and now.
-
Justin M. Hall: [BIS] Going forward, I firmly believe it'll prove to be a solid bet. So, let's see how it plays out.
LATEST REPLIES
-
Justin M. Hall
4/5/12 7:30A ET: {BIS, SPPI} Short Biotech => Back on 1/30/12, I reco'd near-the-money puts on SPPI. Were you paying attention? - View all 16 replies
-
-
-
Justin M. Hall
4/5/12 3:45A ET: { Short Biotech } Reiterating my past take => Look for a bifurcated market to emerge in Q2 2012. I like BIS right now. - View all 2 replies
-
Justin M. Hall: Shares of BIS last traded at $22.86. I officially recommended it on my site at/below $24.
-
Justin M. Hall: I first highlighted the bifurcarted market theme on 3/8/12. Others are beginning to catch on. :-)
-
Justin M. Hall
3/21/12 2:05P ET: [ IBB ] When IBB hits $122, it's time to get short. Consider playing BIS. I continue to like this play at/below $24. - View all 5 replies
-
Justin M. Hall: It might require some work. We did very well with it last year. No BS. I like BIS right here and now.
-
Justin M. Hall: [BIS] Going forward, I firmly believe it'll prove to be a solid bet. So, let's see how it plays out.
-
Justin M. Hall
3/8/12 10:35A ET: [Short Biotech] Look for a bifurcated market to emerge - like soon. I like Short Nasdaq Biotech (BIS) now at/near $25. - View all 4 replies
-
Justin M. Hall: Bottom Line: I like BIS at or below $24. Buy and build this position over time. Don't panic if it falls. Add and stick with it.
-
Justin M. Hall: NOTE: Avoid playing the IBB puts. They're terribly overpriced and don't represent a good value. Stick with BIS shares.
-
Justin M. Hall
1/30/12 5:42A ET: Going along with the short biotech (BIS) theme, investors might consider picking up n-t-m puts on SPPI. - View all 5 replies
-
Justin M. Hall: RSI on daily chart is now at 38.79. Overall, SPPI's chart does not look good for those who remain stubbornly long shares.
-
Justin M. Hall: D: I do not own any positions in SPPI, long or short. I have NO intentions of taking any positions in SPPI within the next 90 days! :-)
-
Justin M. Hall
1/30/12 5:40A ET: Rather than playing FAZ, investors ought to consider building positions in BIS - short biotech. - View all 1 replies
-
-
- View all 1 replies
-
